Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2007 (2007), Article ID 96410, 4 pages
http://dx.doi.org/10.1155/2007/96410
Research Article

Enhancement of a TH1 Immune Response in Amphotericin B-Treated Mucocutaneous Leishmaniasis

Department of Pathology, Faculty of Medicine, University Mayor de San Andrés, Avenue Saavedra 2246, La Paz, Bolivia

Received 6 December 2006; Revised 2 February 2007; Accepted 7 March 2007

Academic Editor: Ali Ouaissi

Copyright © 2007 Washington R. Cuna et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. L. Herwaldt, “Leishmaniasis,” The Lancet, vol. 354, no. 9185, pp. 1191–1199, 1999. View at Publisher · View at Google Scholar
  2. J. P. Dedet, Les Leishmanioses, In: Ellipses (France and Maghreb countries) and Edicef-Hachette (International) eds. AUPELF-UREF Médecine Tropicale collection. Paris, 2003: 13–245.
  3. P. Desjeux, M. Quilici, and J. Lapierre, “On 113 cases of cutaneous leishmaniasis and mucocutaneous leishmaniasis observed in Bolivia. Sero-immunologic study of 71 cases,” Bulletin de la Société de Pathologie Exotique et de ses Filiales, vol. 67, no. 4, pp. 387–395, 1974. View at Google Scholar
  4. C. David, L. Dimier-David, F. Vargas, M. Torrez, and J. P. Dedet, “Fifteen years of cutaneous and mucocutaneous leishmaniasis in Bolivia: a retrospective study,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 87, no. 1, pp. 7–9, 1993. View at Publisher · View at Google Scholar
  5. M. Castes, A. Agnelli, and A. J. Rondon, “Mechanisms associated with immunoregulation in human American cutaneous leishmaniasis,” Clinical and Experimental Immunology, vol. 57, no. 2, pp. 279–286, 1984. View at Google Scholar
  6. J. Convit, M. Ulrich, C. T. Fernandez et al., “The clinical and immunological spectrum of American cutaneous leishmaniasis,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 87, no. 4, pp. 444–448, 1993. View at Publisher · View at Google Scholar
  7. P. D. Marsden, “Mucosal leishmaniasis (“espundia” Escomel, 1911),” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 80, no. 6, pp. 859–876, 1986. View at Publisher · View at Google Scholar
  8. J. R. Perfect, D. L. Granger, and D. T. Durack, “Effects of antifungal agents and γ interferon on macrophage cytotoxicity for fungi and tumor cells,” Journal of Infectious Diseases, vol. 156, no. 2, pp. 316–323, 1987. View at Google Scholar
  9. J. D. Berman and D. J. Wyler, “An in vitro model for investigation of chemotherapeutic agents in leishmaniasis,” Journal of Infectious Diseases, vol. 142, no. 1, pp. 83–86, 1980. View at Google Scholar
  10. J. E. Wolf and S. E. Massof, “In vivo activation of macrophage oxidative burst activity by cytokines and amphotericin B,” Infection and Immunity, vol. 58, no. 5, pp. 1296–1300, 1990. View at Google Scholar
  11. A. G. Vonk, M. G. Netea, N. E. J. Denecker, I. C. M. M. Verschueren, J. W. M. van der Meer, and B. J. Kullberg, “Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B,” Journal of Antimicrobial Chemotherapy, vol. 42, no. 4, pp. 469–474, 1998. View at Publisher · View at Google Scholar
  12. O. Bacellar, H. Lessa, A. Schriefer et al., “Up-regulation of Th1-type responses in mucosal leishmaniasis patients,” Infection and Immunity, vol. 70, no. 12, pp. 6734–6740, 2002. View at Publisher · View at Google Scholar
  13. Y. A. W. Skeiky, J. A. Guderian, D. R. Benson et al., “A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12,” Journal of Experimental Medicine, vol. 181, no. 4, pp. 1527–1537, 1995. View at Publisher · View at Google Scholar
  14. J. K. S. Chia and M. Pollack, “Amphotericin B induces tumor necrosis factor production by murine macrophages,” Journal of Infectious Diseases, vol. 159, no. 1, pp. 113–116, 1989. View at Google Scholar
  15. H. A. Lessa, P. Machado, F. Lima et al., “Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony,” American Journal of Tropical Medicine and Hygiene, vol. 65, no. 2, pp. 87–89, 2001. View at Google Scholar
  16. E. Martin, A. Stuben, A. Gorz, U. Weller, and S. Bhakdi, “Novel aspect of amphotericin B action: accumulation in human monocytes potentiates killing of phagocytosed Candida albicans,” Antimicrobial Agents and Chemotherapy, vol. 38, no. 1, pp. 13–22, 1994. View at Google Scholar
  17. A. D'Andrea, M. Rengaraju, N. M. Valiante et al., “Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells,” Journal of Experimental Medicine, vol. 176, no. 5, pp. 1387–1398, 1992. View at Publisher · View at Google Scholar
  18. N. Weinheber, M. Wolfram, D. Harbecke, and T. Aebischer, “Phagocytosis of Leishmania mexicana amastigotes by macrophages leads to a sustained suppression of IL-12 production,” European Journal of Immunology, vol. 28, no. 8, pp. 2467–2477, 1998. View at Publisher · View at Google Scholar
  19. H. W. Murray, J. Hariprashad, and R. E. Fichtl, “Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine,” Antimicrobial Agents and Chemotherapy, vol. 37, no. 7, pp. 1504–1505, 1993. View at Google Scholar